Driven by these positive developments, in December last year, Celldex initiated a global Phase 3 study evaluating barzolvolimab in patients with ColdU and SD, two chronic inducible urticaria conditions with no approved advanced therapies. Beyond urticaria, the company is still enrolling in Phase 2 studies of barzolvolimab for prurigo nodularis and atopic dermatitis, with preliminary results expected in the second half of 2026. Its other candidate is CDX-622, a bispecific antibody that targets both stem cell ...